1 active not recruiting, 1 recruiting. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Active not recruiting 1, Recruiting 1 |
Follow Aggressive Variant Prostate Carcinoma: new trials by email Literature Review of Aggressive Variant Prostate Carcinoma trials Research Report on Aggressive Variant Prostate Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Zanzalintinib in Men With Aggressive Variant Prostate Cancer Zanzalintinib - Aggressive Variant Prostate Carcinoma | Phase 2 | Recruiting | Deepak Kilari | 30 | 2026-08-19 | 2026-08-28 |
| Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer Cabazitaxel, Carboplatin, Cetrelimab - Aggressive Variant Prostate Carcinoma, Castration-Resistant Prostate Carcinoma | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 120 | 2020-12-29 | 2026-09-09 |
Genital Diseases (1) · Genital Diseases, Male (1) · Genital Neoplasms, Male (1) · Male Urogenital Diseases (1) · Neoplasms (1) · Neoplasms by Site (1) · Prostatic Diseases (1) · Urogenital Diseases (1) · Urogenital Neoplasms (1)
Carboplatin (1) · XRP6258 (1) · cabazitaxel (1) · niraparib (1)
Deepak Kilari (1) · M.D. Anderson Cancer Center (1)
United States (2)
Ana Aparicio (1) · Deepak Kilari, MD (1)